Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors

2017 ◽  
Vol 35 (4) ◽  
pp. 425-431 ◽  
Author(s):  
Alicia Pérez-Calvo ◽  
Francisca Martínez ◽  
Christophe Blockeel ◽  
Elisabeth Clúa ◽  
Ignacio Rodríguez ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Gnrh Antagonist ◽  
Free Interval ◽  
Corifollitropin Alfa ◽  
Gnrh Antagonist Protocol ◽  
Oocyte Donors ◽  
Antagonist Protocol

scholarly journals Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study

2017 ◽  
Vol 34 (5) ◽  
pp. 534-540 ◽  
Author(s):  
Tamara Lerman ◽  
Marion Depenbusch ◽  
Askan Schultze-Mosgau ◽  
Soeren von Otte ◽  
Markus Scheinhardt ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Multiple Dose ◽  
Gnrh Antagonist ◽  
Ovarian Response ◽  
Corifollitropin Alfa

scholarly journals Use of Corifollitropin Alfa for Ovarian Stimulation: A Retrospective Analysis of 804 Women Undergoing IVF/ICSI

2019 ◽  
Vol 01 (02) ◽  
pp. 93-98
Author(s):  
Nhu H. Giang ◽  
Lan N. Vuong ◽  
Toan D. Pham ◽  
Tuong M. Ho
Keyword(s):  
Embryo Transfer ◽  
Ovarian Reserve ◽  
Gnrh Antagonist ◽  
Asian Population ◽  
Poor Responders ◽  
Fresh Embryo Transfer ◽  
Corifollitropin Alfa ◽  
Gnrh Antagonist Protocol ◽  
Oocyte Donors ◽  
Antagonist Protocol

Background: Corifollitropin alfa in GnRH antagonist protocol could provide a friendly treatment for IVF patients. There is limited evidence regarding the outcomes of corifollitropin alfa in ovarian hyperstimulation in Asian population. Methods: This was a retrospective study conducted on IVF women from July 2012 to July 2018. The recruited patients were expected normal responders, expected poor responders and oocyte donors. The patients underwent GnRH antagonist protocol with corifollitropin alfa. Results: There were 804 IVF patients included in the study. The patients were analyzed into: normal ovarian reserve-autologous cycles ([Formula: see text] 36 years and [Formula: see text] 60 kg, n = 33; [Formula: see text] 36 years and [Formula: see text] 60 kg, n [Formula: see text] 9; [Formula: see text] 36 years and [Formula: see text] 50 kg, n [Formula: see text] 204; [Formula: see text] 36 years and [Formula: see text] 50 kg, n [Formula: see text] 52), normal ovarian reserve-donor cycles ([Formula: see text] 60 kg, n [Formula: see text] 234; [Formula: see text] 60 kg, n [Formula: see text] 104) and diminished ovarian reserve cycles (n [Formula: see text] 168). In each group of patients, the pregnancy outcomes of fresh embryo transfer were comparable to those of frozen embryo transfer. Conclusions: Corifollitropin alfa could offer an effective and simple treatment option for all groups of patients without PCOS.

scholarly journals Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study

2021 ◽  
Author(s):  
Gabriele S. Merki-Feld ◽  
Peter S. Sandor ◽  
Rossella E. Nappi ◽  
Heiko Pohl ◽  
Christoph Schankin
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Natural Cycle ◽  
Free Interval ◽  
Migraine Frequency ◽  
Combined Hormonal Contraception ◽  
Migraine Onset

AbstractMany studies have described the features of menstrually related migraines but there is a lack of knowledge regarding the features of migraine in combined hormonal contraceptive users (CHC). Hormone-withdrawal migraines in the pill-free period could differ from those in the natural cycle. Gynaecologic comorbidities, like dysmenorrhea and endometriosis, but also depression or a family history might modify the course of migraine. A better understanding of migraine features linked to special hormonal situations could improve treatment. For this prospective cohort study, we conducted telephone interviews with women using a CHC and reporting withdrawal migraine to collect information on migraine frequency, intensity, triggers, symptoms, pain medication, gynaecologic history and comorbidities (n = 48). A subset of women agreed to also document their migraines in prospective diaries. The mean number of migraine days per cycle was 4.2 (± 2.7). Around 50% of these migraines occurred during the hormone-free interval. Migraine frequency was significantly higher in women who suffered from migraine before CHC start (5.0 ± 3.1) (n = 22) in comparison to those with migraine onset after CHC start (3.5 ± 2.1) (n = 26). Menstrually related attacks were described as more painful (57.5%), especially in women with migraine onset before CHC use (72%) (p < 0.02). Comorbidities were rare, except dysmenorrhea. The majority of migraine attacks in CHC users occur during the hormone-free interval. Similar as in the natural cycle, hormone-withdrawal migraines in CHC users are very intense and the response to acute medication is less good, especially in those women, who developed migraine before CHC use.

scholarly journals Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: A randomized controlled pilot study

2014 ◽  
Vol 29 (7) ◽  
pp. 1500-1507 ◽  
Author(s):  
C. Blockeel ◽  
N. P. Polyzos ◽  
L. Derksen ◽  
M. De Brucker ◽  
V. Vloeberghs ◽  
...  
Keyword(s):  
Pilot Study ◽  
Gnrh Antagonist ◽  
Randomized Controlled ◽  
Corifollitropin Alfa ◽  
Gnrh Antagonist Protocol ◽  
Antagonist Protocol

scholarly journals Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0149615 ◽  
Author(s):  
Georg Griesinger ◽  
Pierre J. M. Verweij ◽  
Davis Gates ◽  
Paul Devroey ◽  
Keith Gordon ◽  
...  
Keyword(s):  
Ovarian Hyperstimulation Syndrome ◽  
Gnrh Antagonist ◽  
Ovarian Hyperstimulation ◽  
Corifollitropin Alfa ◽  
Gnrh Antagonist Protocol ◽  
Antagonist Protocol

scholarly journals No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa

2011 ◽  
Vol 23 (4) ◽  
pp. 449-456 ◽  
Author(s):  
Kevin J. Doody ◽  
Paul Devroey ◽  
Arthur Leader ◽  
Han Witjes ◽  
Bernadette M. Mannaerts
Keyword(s):  
Gnrh Antagonist ◽  
Corifollitropin Alfa ◽  
Gnrh Antagonist Protocol ◽  
Antagonist Protocol

scholarly journals Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity

2011 ◽  
Vol 26 (8) ◽  
pp. 2200-2208 ◽  
Author(s):  
R. J. Norman ◽  
F. Zegers-Hochschild ◽  
B. S. Salle ◽  
J. Elbers ◽  
E. Heijnen ◽  
...  
Keyword(s):  
Ovarian Stimulation ◽  
Gnrh Antagonist ◽  
Corifollitropin Alfa ◽  
Gnrh Antagonist Protocol ◽  
Antagonist Protocol
Sign in / Sign up

Export Citation Format

Share Document